131 related articles for article (PubMed ID: 1904269)
1. Experience with salvage regimens at M.D. Anderson Hospital.
Cabanillas F
Ann Oncol; 1991 Jan; 2 Suppl 1():31-2. PubMed ID: 1904269
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas.
Romaguera JE; Rodriguez MA; Hagemeister FB; McLaughlin P; Swan F; Moore DF; Sarris AH; Younes A; Hill D; Cabanillas F
Invest New Drugs; 1994; 12(3):217-22. PubMed ID: 7896540
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience.
Rodriguez-Monge EJ; Cabanillas F
Hematol Oncol Clin North Am; 1997 Oct; 11(5):937-47. PubMed ID: 9336723
[TBL] [Abstract][Full Text] [Related]
4. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
Rodriguez MA; Cabanillas FC; Velasquez W; Hagemeister FB; McLaughlin P; Swan F; Romaguera JE
J Clin Oncol; 1995 Jul; 13(7):1734-41. PubMed ID: 7602363
[TBL] [Abstract][Full Text] [Related]
5. MINE-ESHAP salvage therapy for recurrent and refractory lymphomas.
Cabanillas F; Rodriguez MA
Semin Hematol; 1994 Apr; 31(2 Suppl 3):30. PubMed ID: 8073305
[No Abstract] [Full Text] [Related]
6. Non-Hodgkin's lymphomas: a review of the M.D. Anderson experience.
Cabanillas F
Semin Oncol; 1992 Feb; 19(1 Suppl 1):11-3. PubMed ID: 1384134
[TBL] [Abstract][Full Text] [Related]
7. Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.
Romaguera JE; Hagemeister FB; McLaughlin P; Rodriguez MA; Bachier C; Preti H; Sarris AH; Weber D; Younes A; Cabanillas F
Leuk Lymphoma; 1998 Dec; 32(1-2):97-106. PubMed ID: 10037005
[TBL] [Abstract][Full Text] [Related]
8. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease.
Cabanillas F; Velasquez WS; McLaughlin P; Jagannath S; Hagemeister FB; Redman JR; Swan F; Rodriguez MA
Semin Hematol; 1988 Apr; 25(2 Suppl 2):47-50. PubMed ID: 3041599
[TBL] [Abstract][Full Text] [Related]
9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas.
Rodriguez MA; Cabanillas FC; Hagemeister FB; McLaughlin P; Romaguera JE; Swan F; Velasquez W
Ann Oncol; 1995 Jul; 6(6):609-11. PubMed ID: 8573542
[TBL] [Abstract][Full Text] [Related]
11. Experience with ifosfamide combinations in malignant lymphomas.
Cabanillas F
Semin Oncol; 1989 Feb; 16(1 Suppl 3):78-81. PubMed ID: 2649986
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide combinations in lymphoma.
Cabanillas F
Semin Oncol; 1990 Apr; 17(2 Suppl 4):58-62. PubMed ID: 2333524
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
[TBL] [Abstract][Full Text] [Related]
14. Results of MIME salvage regimen for recurrent or refractory lymphoma.
Cabanillas F; Hagemeister FB; McLaughlin P; Velasquez WS; Riggs S; Fuller L; Smith T
J Clin Oncol; 1987 Mar; 5(3):407-12. PubMed ID: 3819806
[TBL] [Abstract][Full Text] [Related]
15. Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas.
Wilder RB; Rodriguez MA; Tucker SL; Ha CS; Hess MA; Cabanillas FF; Cox JD
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):743-9. PubMed ID: 11395243
[TBL] [Abstract][Full Text] [Related]
16. Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas.
Nowrousian MR; Anders CH; Niederle N; Nagel-Hiemke M; Moritz T; Seeber S; Schmidt CG
Ann Oncol; 1991 Jan; 2 Suppl 1():25-30. PubMed ID: 1710486
[TBL] [Abstract][Full Text] [Related]
17. Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.
Dinçol D; Içli F; Karaoğuz H; Cay F; Arican A; Demirkazik A; Akbulut H
Acta Oncol; 1995; 34(7):937-40. PubMed ID: 7492384
[TBL] [Abstract][Full Text] [Related]
18. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease and non-Hodgkin's lymphoma. The Swedish Lymphoma Study Group.
Enblad G; Glimelius B; Hagberg H; Lindemalm C
Acta Oncol; 1990; 29(3):297-301. PubMed ID: 2363941
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
[TBL] [Abstract][Full Text] [Related]
20. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for non-Hodgkin's lymphomas: a Swedish national prospective study. Swedish Lymphoma Study Group.
Enblad G; Hagberg H; Glimelius B
Acta Oncol; 1996; 35(2):165-70. PubMed ID: 8639311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
